secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001104659-23-076136
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share
----------------------------------------------------------------------------

- Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.
- Clay Siegall to become Chairman and CEO; board to include 2 from Morphimmune, 1 from Immunome, 4 independents.
- PIPE financing of ~$125M at $5.75/share (or $5.91 for affiliates) from Enavate, EcoR1, Redmile.
- Siegall employment agreement: $650K base, 50% bonus target, option for 2.14M shares at $5.91.
- Closing conditions include S-4 effectiveness, Nasdaq listing, PIPE proceeds of $125M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/0001104659-23-076136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/tm2320045d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-076136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer